Dermira, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2025-07-02: Study NCT06906497; Company role Collaborator; Phase Phase 4; Status Active not recruiting.
- 2022-10-18: Study NCT05559359; Company role Collaborator; Phase Phase 3; Status Active not recruiting.
- 2020-06-15: Study NCT04392154; Company role Collaborator; Phase Phase 3; Status Completed.
- 2020-02-11: Study NCT04250350; Company role Collaborator; Phase Phase 3; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2025-07-02 | NCT06906497 Lebrikizumab in Moderate-to-severe Atopic Dermatitis | Collaborator Lead: Johann E Gudjonsson MD PhD | Phase 4 | Active not recruiting | Atopic Dermatitis | 48 | 2028-07 |
| 2022-10-18 | NCT05559359 A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis | Collaborator Lead: Eli Lilly and Company | Phase 3 | Active not recruiting | Atopic Dermatitis; Eczema | 377 | 2026-12 |
| 2020-06-15 | NCT04392154 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) | Collaborator Lead: Eli Lilly and Company | Phase 3 | Completed Results posted | Atopic Dermatitis | 1,153 | 2025-04-22 |
| 2020-02-11 | NCT04250350 Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis | Collaborator Lead: Eli Lilly and Company | Phase 3 | Completed Results posted | Atopic Dermatitis | 206 | 2022-06-22 |
| 2020-02-03 | NCT04250337 Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. | Collaborator Lead: Eli Lilly and Company | Phase 3 | Completed Results posted | Atopic Dermatitis | 228 | 2021-09-16 |
| 2019-10-29 | NCT04178967 Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis | Collaborator Lead: Eli Lilly and Company | Phase 3 | Completed Results posted | Atopic Dermatitis | 445 | 2022-04-28 |
| 2019-09-24 | NCT04146363 Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) | Collaborator Lead: Eli Lilly and Company | Phase 3 | Completed Results posted | Atopic Dermatitis | 424 | 2022-05-03 |
| 2018-01-30 | NCT03443024 A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis | Collaborator Lead: Eli Lilly and Company | Phase 2 | Completed Results posted | Atopic Dermatitis | 280 | 2019-05-23 |
| 2017-03-21 | NCT03127956 A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris | Lead sponsor | Phase 3 | Completed Results posted | Acne Vulgaris | 748 | 2018-04-27 |
| 2017-02-06 | NCT03073486 A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris | Lead sponsor | Phase 3 | Completed Results posted | Acne Vulgaris | 744 | 2017-12-21 |
| 2016-12-27 | NCT03028363 A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris | Lead sponsor | Phase 3 | Completed Results posted | Acne Vulgaris | 759 | 2017-11-28 |
| 2015-04 | NCT02431052 A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris | Lead sponsor | Phase 2 | Completed Results posted | Acne Vulgaris | 420 | 2016-04 |
| 2013-10 | NCT01993446 A Safety and Efficacy Study of DRM02 in Subjects With Rosacea | Lead sponsor | Phase 2 | Completed | Rosacea | 30 | 2014-03 |
| 2013-10 | NCT01993433 A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis | Lead sponsor | Phase 2 | Completed | Psoriasis | 23 | 2014-03 |
| 2013-10 | NCT01993420 A Safety and Efficacy of DRM02 in Subjects With Atopic Dermatitis | Lead sponsor | Phase 2 | Completed | Atopic Dermatitis | 21 | 2014-03 |
| 2013-08 | NCT01936324 A Safety, Tolerability and Preliminary Efficacy Study of DRM01B Topical Gel | Lead sponsor | Phase 1, Phase 2 | Completed Results posted | Acne Vulgaris | 114 | 2014-06 |
| 2013-04 | NCT01830764 Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers | Lead sponsor | Phase 1 | Completed | Acne Vulgaris | 12 | 2013-06 |
| 2011-12 | NCT01490736 Phase 1/2 Sequentially Staged Safety Study in Healthy Subjects and Subjects With Mild Acne | Lead sponsor | Phase 1, Phase 2 | Completed | Acne | 129 | 2013-06 |